Novartis to acquire Advanced Accelerator Applications for oncology portfolio

Tuesday, October 31, 2017

Novartis has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Advanced Accelerator Applicationsis a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines including Lutathera (177Lu-DOTATATE), a first-in-class RLT product for neuroendocrine tumors (NETs).

[Read More]

Novartis collaborates with Cyndi Lauper on song in honor of World Psoriasis Day

Tuesday, October 24, 2017

Novartis announced that Grammy, Tony and Emmy award-winning singer, songwriter, actress and activist Cyndi Lauper has released a new song, Hope, in honor of World Psoriasis Day. Inspired by psoriasis patients and Lauper’s own experience living with the disease, Hope is part of the SEE ME campaign, an initiative that celebrates patients’ success stories and encourages others living with plaque psoriasis to seek ways to get back to doing the things they want to do.

[Read More]

NIH partners with 11 biopharmaceutical companies on cancer immunotherapy strategies

Friday, October 13, 2017

The NIH and 11 biopharmaceutical companies launched the Partnership for Accelerating Cancer Therapies (PACT), a five-year public-private research collaboration totaling $215 million as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers—standardized biological markers of disease and treatment response—to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the Foundation for the National Institutes of Health (FNIH), with the Food and Drug Administration serving in an advisory role. 

[Read More]

TransCelerate BioPharma adds Novartis

Monday, September 18, 2017

TransCelerate BioPharma announces the addition of Novartis to the biopharmaceutical nonprofit organization, growing the consortium to 19 biopharmaceutical companies. In addition, TransCelerate membership have elected Elliott Levy, M.D., Senior Vice President, Global Development at Amgen as the new Chair of the Board of the Directors and David Nicholson, Ph.D., Executive Vice President, and Chief R&D Officer at Allergan, will assume the Vice Chair role.

[Read More]

Novartis launches smartphone research study in multiple sclerosis

Friday, August 25, 2017

Novartis announced the launch of a mobile research study for people with multiple sclerosis (MS) that collects data via their smartphone, without the need for clinic visits. The study, Evaluation of Evidence from Smart Phone Sensors and Patient-Reported Outcomes in Participants with Multiple Sclerosis (elevateMS), is designed to collect sensor-based data from physical tasks and symptoms. It aims to improve understanding of the daily challenges patients with MS can have and to uncover new potential measurements of treatment effectiveness through real-time data collection from participants in their everyday life.

[Read More]

Novartis, Medicines For Malaria Venture launch KAF156 trial in Africa

Tuesday, August 22, 2017

Novartis and Medicines for Malaria Venture (MMV) have launched a patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite. The trial will test the efficacy of KAF156 in combination with a new, improved formulation of the existing antimalarial lumefantrine. The first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few months.

[Read More]